SIDP’s Recap of IDWeek 2019 - Part 1: Late Breaker Trials and #WhyIVaccinate; Practice-changing Publications ft. David van Duin

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 
 View more SIDPEC Activities
 

Activity Description

Ryan Shields and Erin McCreary review key posters, presentations, and other data from the IDWeek 2019 meeting.

Episode 1: Late Breaker Trials and #WhyIVaccinate
Learn about some big announcements from IDWeek 2019 including the #WhyIVaccinate movement, data from late-breaker clinical trials, new partnerships, and more!

Episode 2: Practice-changing publications ft. David van Duin
David van Duin joins panelists to review the "Clinical Trials That Might Change Your Practice" session from IDWeek 2019 including trials in bacteriology, virology, and mycology.

Learning Objectives

The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:

  • Describe a late-breaking clinical trial presented at IDWeek 2019.
  • Explain #WhyIVaccinate from IDWeek 2019.
  • Discuss recently published clinical trials in bacteriology that impact the care of patients with infectious diseases.
  • Discuss recently published clinical trials in mycology and virology that impact the care of patients with infectious diseases.

Faculty

Erin K. McCreary, PharmD, BCPS, BCIDP
Antimicrobial Stewardship/Infectious Diseases Clinical Pharmacist
University of Pittsburgh Medical Center
Pittsburgh, PA

Ryan K. Shields, PharmD, MS
Associate Professor of Medicine
University of Pittsburgh
Pittsburgh, PA

CE Accreditation

Release Date: 11-1-2019
Expiration Date: 11-1-2022

Pharmacists

This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-518-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.8 contact hour (0.18 CEU) in states that recognize ACPE providers. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

BCIDP

The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. BCIDP accreditation begins 11/1/2019 for this activity and is available for one year from this date.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. McCreary has no relevant commercial or financial relationships to disclose. Dr. Shields has served as a speaker and/or consultant for Allergan, Entasis, Menarini, Merck, Nabriva, Pfizer, Shionogi, and T2Biosystems, and is an advisory board member for Pfizer.

Funding

This activity is provided by ProCE, Inc. and SIDP.

    

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.